metabolic disease research has been the elucidation of links between inflammatory signaling pathways and glucose/lipid metabolism. An early catalyst for research in this area was the discovery by Hotamisligil and Spiegelman that the cytokine TNFα is produced by adipose tissue in obese animals and contributes to the development of insulin resistance (Hotamisligil et al., 1993) . A number of other cytokines and signaling molecules-including IL-6, JNK, IKKβ, and SOCS proteins-have subsequently been linked to insulin resistance induced by obesity (Shoelson et al., 2006; Wellen and Hotamisligil, 2005) . A common theme to emerge from many of these studies is that inflammatory effector pathways such as those activated by JNK and NF-κB directly antagonize the actions of insulin in metabolic tissues such as liver, fat, and skeletal muscle (Hotamisligil, 2006) . Recent studies have also highlighted a potentially important role for adipose tissue macrophages in the production of inflammatory mediators and the development of insulin resistance in obese mice (Weisberg et al., 2003; Xu et al., 2003) . Although the exact triggers for macrophage accumulation in obese adipose tissue are not clear yet, the chemokine MCP-1 and its receptor CCR2 have been shown to be involved in this process (Neels and Olefsky, 2006) . Flier and colleagues have recently shown that Toll-like receptor 4 (TLR4)-which mediates activation of the NF-κB pathway in response to bacterial lipopolysaccharide-is also activated by nutritional fatty acids. This observation suggests a provocative mechanism whereby free fatty acids, levels of which are often increased in obesity and diabetes, may actually cause inflammation in metabolic tissues (Shi et al., 2006) . Wellen et al. (2007) now identify the transmembrane protein STAMP2 as a factor that links inflammatory and diet-derived signals to adipocyte function and systemic metabolism. The authors used transcriptional profiling to search for genes that were downregulated in adipose tissue of obese (ob/ob) mice both in the absence of TNFα and upon treatment with the PPARγ agonist thiazolidinedione (TZD). STAMP2 was selected for detailed analysis based on its preferential expression in adipose tissue. Studies in the 3T3-L1 adipocyte cell line revealed that expression of STAMP2 was induced not only by TNFα but also by nutritional stimuli such as oleic acid or serum. In vivo, STAMP2 expression was induced by feeding, and this physiologic response was lost in ob/ob mice or in mice rendered obese through a high-fat diet. The pattern of STAMP2 expression and regulation raised the possibility that this protein might coordinate inflammatory responses with metabolic pathways in adipose tissue.
To define the physiological role of STAMP2, Wellen et al. performed loss-of-function studies in vitro and in vivo. In 3T3-L1 adipocytes, knockdown of STAMP2 expression with small interfering (si)RNAs resulted in augmented IL-6 production in response to either TNFα or high glucose stimulation. Loss of STAMP2 was also associated with decreased responses to insulin, including reduced phosphorylation of insulin signaling molecules such as the insulin receptor and Akt, and reduced glucose transport. In line with these in vitro results, loss of STAMP2 expression in vivo was sufficient to cause inflammation in adipose tissue. STAMP2 knockout mice exhibited increased expression of inflammatory mediators such as TNFα, IL-6, MCP-1, SOCS-3, and haptoglobin as well as increased numbers of macrophages in their adipose tissue under basal conditions on a normal diet. Furthermore, consistent with the increased cytokine production observed in cultured adipocytes, induction of IL-6 and SOCS-3 expression in response to glucose and lipid administration was augmented in STAMP2-deficient mice.
The hypothesis that inflammation in metabolic tissues contributes to the development of insulin resistance is the focus of intense research. With their analysis of the STAMP2 knockout mice, Wellen et al. provide strong support for this notion. In short, STAMP2 deficiency mimics many aspects of metabolic syndrome in humans. At the systemic level, STAMP2 deficiency results in impaired insulin sensitivity and dysli- pidemia (abnormal blood lipid levels). Mice lacking STAMP2 had markedly higher plasma glucose, insulin, triglyceride, and cholesterol levels and developed hepatic steatosis (fatty liver). They also showed impaired glucose metabolism in key metabolic tissues (liver, skeletal muscle, and adipose). At the molecular level, these physiologic defects were associated with impaired insulin receptor signaling in liver and adipose tissue. The ability of STAMP2-which is expressed primarily in adipocytes-to impact insulin sensitivity in liver and muscle raises the possibility that factors secreted by adipocytes into the circulation (adipokines) may mediate this crosstalk. One of the paradoxes raised by the finding that fatty acids activate Toll-like receptors and inflammatory signaling pathways is the implication that nutrient abundance, such as occurs during feeding, may be a trigger for inflammation in adipose tissue. The authors propose that STAMP2 may be a counter-regulatory factor that prevents inappropriate activation of inflammatory pathways during fluctuations in nutrient exposure or under nutrient-rich conditions such as feeding. STAMP2 may therefore serve to integrate inflammatory pathways and metabolic homeostasis ( Figure  1 ). Although this idea is supported by the observation that loss of STAMP2 expression compromises adipocyte function, it will be important to determine whether elevation of STAMP2 expression actively protects adipocytes against inflammatory challenge.
STAMPing out Inflammation
As with any new player in inflammation and metabolism, a number of questions remain to be answered. Among the most important unresolved issues is the cellular mechanism through which STAMP2 exerts its inflammatory and metabolic effects. The fact that it is a transmembrane protein immediately suggests several possibilities. Interestingly, STAMP2 belongs to the STAMP or STEAP family of six transmembrane domain proteins (Ohgami et al., 2005) . Members of this family are metalloreductases, which are important for the cellular import of iron and copper. Is this activity of STAMP2 required for its suppressive effect on inflammatory responses and for its role in maintaining proper insulin signaling in adipocytes? Does the inability to properly handle iron or copper in adipocytes lead to inflammation? If so, future studies may shed new light on the role of metal metabolism in immune responses and glucose metabolism.
Another provocative feature of STAMP2 is its dynamic expression: STAMP2 is induced by nutrients/ feeding and by cytokines such as TNFα. What are the molecular pathways that regulate STAMP2 expression and how are these pathways disrupted in obese/diabetic animals? Does loss of STAMP2 regulation in obese/diabetic mice play a causal role in the development of insulin resistance and increased inflammatory tone in adipose tissue of these animals? Future studies should determine whether forced expression of STAMP2 in adipose tissue of obese/diabetic mice rescues aspects of the defective metabolic or inflammatory phenotype. Finally, although the new work focuses primarily on the metabolic impact of STAMP2, it will be interesting to address the potential role of STAMP2 in immunity and inflammation.
